Paper Details

  1. Home
  2. Paper Details

Incidence and risk of hypertension associated with cabozantinib in cancer patients: a systematic review and meta-analysis.

Author: ShaoYongjie, WangKunjie, ZhangXi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Cabozantinib, a tyrosine kinase inhibitor, is associated with a high incidence of hypertension in cancer patients.
Paper Details　
Original Abstract of the Article :
Cabozantinib (XL184) is an oral inhibitor of multiplereceptor tyrosine kinases including mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2). Hypertension is one of its major side effects, but the incidence rate and overall risk has not been syst...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/17512433.2016.1190269

データ提供：米国国立医学図書館（NLM）

Cabozantinib: A Powerful Tool with Potential Side Effects

The desert of [cancer] is a challenging terrain, and researchers are constantly seeking new weapons to combat this formidable foe. This study focuses on the potential side effects of [cabozantinib], a drug used to treat various [cancers]. It’s like navigating a treacherous desert, where even powerful tools can have unforeseen consequences. The authors conducted a [systematic review] and [meta-analysis] to investigate the incidence and risk of developing [hypertension] in patients receiving [cabozantinib].

Hypertension: A Potential Side Effect in the Desert of Cancer Treatment

The study found that [hypertension] is a common side effect of [cabozantinib]. It’s like encountering a sudden sandstorm in the desert, a reminder that even powerful treatments can have unexpected challenges. The study highlights the importance of closely monitoring patients receiving [cabozantinib] for signs of [hypertension].

Navigating the Desert of Cancer Treatment: Staying Vigilant

This study emphasizes the importance of being vigilant about potential side effects when treating [cancer]. It’s like navigating the desert with a keen eye for danger, ensuring that we are prepared for the unexpected. Further research is needed to understand the specific risks and benefits of [cabozantinib] and develop strategies for managing potential side effects.

Dr.Camel's Conclusion

This research highlights the importance of monitoring hypertension in patients receiving cabozantinib, a drug used to treat various cancers. It emphasizes the need for vigilance in navigating the desert of cancer treatment, ensuring that we are prepared for potential side effects and equipped to manage them effectively.

Date :
  1. Date Completed 2017-03-10
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27181268

DOI: Digital Object Identifier

10.1080/17512433.2016.1190269

Related Literature

Article Analysis
・Side Effects of cabozantinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.